219 related articles for article (PubMed ID: 32997997)
1. Activation of CpG-Rich Promoters Mediated by MLL Drives MOZ-Rearranged Leukemia.
Miyamoto R; Okuda H; Kanai A; Takahashi S; Kawamura T; Matsui H; Kitamura T; Kitabayashi I; Inaba T; Yokoyama A
Cell Rep; 2020 Sep; 32(13):108200. PubMed ID: 32997997
[TBL] [Abstract][Full Text] [Related]
2. Leukemogenesis via aberrant self-renewal by the MLL/AEP-mediated transcriptional activation system.
Yokoyama A
Cancer Sci; 2021 Oct; 112(10):3935-3944. PubMed ID: 34251718
[TBL] [Abstract][Full Text] [Related]
3. [The mechanism of MLL-rearranged leukemogenesis and its targeted therapies].
Yokoyama A
Rinsho Ketsueki; 2021; 62(8):988-997. PubMed ID: 34497239
[TBL] [Abstract][Full Text] [Related]
4. Role of the MOZ/MLL-mediated transcriptional activation system for self-renewal in normal hematopoiesis and leukemogenesis.
Yokoyama A
FEBS J; 2022 Dec; 289(24):7987-8002. PubMed ID: 34482632
[TBL] [Abstract][Full Text] [Related]
5. RNA Polymerase II-Dependent Transcription Initiated by Selectivity Factor 1: A Central Mechanism Used by MLL Fusion Proteins in Leukemic Transformation.
Yokoyama A
Front Genet; 2018; 9():722. PubMed ID: 30693017
[TBL] [Abstract][Full Text] [Related]
6. Cooperative gene activation by AF4 and DOT1L drives MLL-rearranged leukemia.
Okuda H; Stanojevic B; Kanai A; Kawamura T; Takahashi S; Matsui H; Takaori-Kondo A; Yokoyama A
J Clin Invest; 2017 May; 127(5):1918-1931. PubMed ID: 28394257
[TBL] [Abstract][Full Text] [Related]
7. MOZ/ENL complex is a recruiting factor of leukemic AF10 fusion proteins.
Komata Y; Kanai A; Maeda T; Inaba T; Yokoyama A
Nat Commun; 2023 Apr; 14(1):1979. PubMed ID: 37031220
[TBL] [Abstract][Full Text] [Related]
8. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
9. MLL fusion proteins link transcriptional coactivators to previously active CpG-rich promoters.
Okuda H; Kawaguchi M; Kanai A; Matsui H; Kawamura T; Inaba T; Kitabayashi I; Yokoyama A
Nucleic Acids Res; 2014 Apr; 42(7):4241-56. PubMed ID: 24465000
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional activation by MLL fusion proteins in leukemogenesis.
Yokoyama A
Exp Hematol; 2017 Feb; 46():21-30. PubMed ID: 27865805
[TBL] [Abstract][Full Text] [Related]
11. HBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesis.
Takahashi S; Kanai A; Okuda H; Miyamoto R; Komata Y; Kawamura T; Matsui H; Inaba T; Takaori-Kondo A; Yokoyama A
Elife; 2021 Aug; 10():. PubMed ID: 34431785
[TBL] [Abstract][Full Text] [Related]
12. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
Wang WT; Chen TQ; Zeng ZC; Pan Q; Huang W; Han C; Fang K; Sun LY; Yang QQ; Wang D; Luo XQ; Sun YM; Chen YQ
J Hematol Oncol; 2020 Jun; 13(1):78. PubMed ID: 32552847
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.
Paggetti J; Largeot A; Aucagne R; Jacquel A; Lagrange B; Yang XJ; Solary E; Bastie JN; Delva L
Oncogene; 2010 Sep; 29(36):5019-31. PubMed ID: 20581860
[TBL] [Abstract][Full Text] [Related]
14. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
[TBL] [Abstract][Full Text] [Related]
15. AF4 uses the SL1 components of RNAP1 machinery to initiate MLL fusion- and AEP-dependent transcription.
Okuda H; Kanai A; Ito S; Matsui H; Yokoyama A
Nat Commun; 2015 Nov; 6():8869. PubMed ID: 26593443
[TBL] [Abstract][Full Text] [Related]
16. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
17. Plzf drives MLL-fusion-mediated leukemogenesis specifically in long-term hematopoietic stem cells.
Ono R; Masuya M; Nakajima H; Enomoto Y; Miyata E; Nakamura A; Ishii S; Suzuki K; Shibata-Minoshima F; Katayama N; Kitamura T; Nosaka T
Blood; 2013 Aug; 122(7):1271-83. PubMed ID: 23838347
[TBL] [Abstract][Full Text] [Related]
18. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
[TBL] [Abstract][Full Text] [Related]
19. The molecular functions of common and atypical MLL fusion protein complexes.
Takahashi S; Yokoyama A
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194548. PubMed ID: 32320750
[TBL] [Abstract][Full Text] [Related]
20. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
